Reduced tyrosine phosphorylation of P210BCR-ABL and lack of STAT5 activation in BCR-ABL-transduced IL-3-/- primitive hematopoietic cells.

被引：0
|
作者：
Jiang, XY [1 ]
Yip, C [1 ]
Eisterer, W [1 ]
Eaves, A [1 ]
Eaves, C [1 ]
机构：
[1] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
395
引用
下载
收藏
页码：92A / 92A
页数：1
相关论文
共 50 条
  • [31] SHC PHOSPHORYLATION IN MYELOID CELLS IS REGULATED BY GM-CSF, IL-3, STEEL FACTOR AND IS CONSTITUTIVELY INCREASED BY P210(BCR ABL)
    MATSUGUCHI, T
    SALGIA, R
    HALLEK, M
    EDER, M
    DRUKER, B
    ERNST, T
    GRIFFIN, JD
    BLOOD, 1993, 82 (10) : A438 - A438
  • [32] RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells
    Futami, M.
    Hatano, T.
    Soda, Y.
    Kobayashi, S.
    Miyagishi, M.
    Tojo, A.
    LEUKEMIA, 2008, 22 (06) : 1131 - 1138
  • [33] RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells
    M Futami
    T Hatano
    Y Soda
    S Kobayashi
    M Miyagishi
    A Tojo
    Leukemia, 2008, 22 : 1131 - 1138
  • [34] Altered tyrosine phosphorylation of JAK1 and STAT1 proteins in 32D cells overexpressing P210(BCR-ABL) oncoprotein.
    Guo, XYD
    Henderson, YC
    Greenberger, J
    Deisseroth, AB
    JOURNAL OF INVESTIGATIVE MEDICINE, 1996, 44 (03) : A234 - A234
  • [35] RNAi-Mediated silencing of p190Bcr-Abl inactivates stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-Expressing leukemia cells
    Futami, Muneyoshi
    Hatano, Toshiyuki
    Soda, Yasushi
    Kobayashi, Seiichiro
    Miyagishi, Makoto
    Tojo, Arinobu
    BLOOD, 2007, 110 (11) : 819A - 819A
  • [36] STAT5 activation by BCR/ABL is dependent on its intact SH3 and SH2 domains and is required for leukemogenesis.
    Nieborowska-Skorska, M
    Wasik, MA
    Salomoni, F
    Kitamura, T
    Calabretta, B
    Skorski, T
    BLOOD, 1998, 92 (10) : 91A - 91A
  • [37] In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C
    T Kindler
    F Breitenbuecher
    S Kasper
    T Stevens
    B Carius
    H Gschaidmeier
    C Huber
    T Fischer
    Leukemia, 2003, 17 : 999 - 1009
  • [38] ANALYSIS OF P210BCR-ABL TYROSINE PROTEIN-KINASE ACTIVITY IN VARIOUS SUBTYPES OF PHILADELPHIA CHROMOSOME-POSITIVE CELLS FROM CHRONIC MYELOGENOUS LEUKEMIA PATIENTS
    MAXWELL, SA
    KURZROCK, R
    PARSONS, SJ
    TALPAZ, M
    GALLICK, GE
    KLOETZER, WS
    ARLINGHAUS, RB
    KOUTTAB, NM
    KEATING, MJ
    GUTTERMAN, JU
    CANCER RESEARCH, 1987, 47 (06) : 1731 - 1739
  • [39] A novel tool for the detection of phosphatidylinositol-(3,4,5)-trisphosphate in primitive hematopoietic stem cells: Characterization of the response to IL-3 and Bcr-Abl.
    Xenaki, D
    Gray, A
    Downes, CP
    Owen-Lynch, PJ
    BLOOD, 2001, 98 (11) : 290A - 291A
  • [40] P210 tyrosine kinase regulates the expression of 14-3-3sigma in hematopoietic progenitors expressing the BCR-ABL fusion gene.
    Santucci, MA
    Mancini, M
    Zuffa, E
    Brusa, G
    Barbieri, E
    BLOOD, 2005, 106 (11) : 292B - 292B
12345